Westpac Director Peter Nash Avoids Major Investor Backlash Amid ASX Scrutiny 
FDA Pilot Program Eases Rules for Nicotine Pouch Makers 
SpaceX Insider Share Sale Values Company Near $800 Billion Amid IPO Speculation 
Bayer’s Stroke Drug Achieves Breakthrough Trial Results, Boosting Market Confidence 
Canada Loses Measles-Free Status After Nearly 30 Years Amid Declining Vaccination Rates 
Oil Prices Edge Higher as U.S. Seizes Sanctioned Venezuelan Tanker 
Global Forex Markets Brace for Fed Decision as Yen Extends Weakness 
Hong Kong Cuts Base Rate as HKMA Follows U.S. Federal Reserve Move 
China to Add Eli Lilly’s Mounjaro to National Health Insurance in 2025 
Major Drugmakers Slash U.S. Prices and Sell Directly to Patients Amid Trump’s Push for Affordable Medicines 
Novo Nordisk and Eli Lilly Lower Prices for Weight-Loss Drugs Amid U.S. Agreement 
Obamacare Premiums Set to Double in 2026 as Subsidy Expiration Looms Amid U.S. Shutdown 
Moore Threads Stock Slides After Risk Warning Despite 600% Surge Since IPO 
Eli Lilly’s Weight-Loss Pill Nears Fast-Track FDA Approval as Profits Surge on Global Demand 
Asian Currencies Steady as Fed Delivers Hawkish Rate Cut; Aussie and Rupee Under Pressure 
Fed Near Neutral Signals Caution Ahead, Shifting Focus to Fixed Income in 2026 
South Korean pharmaceutical and biotech companies are collaborating to develop new drugs using artificial intelligence (AI).
AI can predict whether a chemical compound is suitable for human use, thereby speeding up the identification of potential substances and enabling the selection of appropriate clinical patients.
There are over 100 cases where candidate substances for new drugs are under development using AI, with over 50 percent carried out through collaborations between domestic and foreign companies, according to the Korea Pharmaceutical and Bio-pharma Manufacturers Association.
HK inno.N Corp. and AinB recently signed an MOU to identify a new antibody candidate substance for cell and gene therapies and establish an antigen design platform for vaccine development.
Last year, Pharos iBio inked a deal with Yuhan Corp. to promote the joint study and technology transfer of the AI-based KRAS inhibitor.
This company is now carrying out a phase 1 clinical trial in Korea and Australia after developing PHI-101, a candidate substance for the treatment of leukemia, using its AI platform, Chemiverse.
Moreover, Oncocross, which has AI technology to identify the optimal disease for drugs, signed a joint study and development contract with Boryung Corp. in February to expand the indications of hypertension treatment.
